MY170117A - Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors - Google Patents

Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

Info

Publication number
MY170117A
MY170117A MYPI2014000238A MYPI2014000238A MY170117A MY 170117 A MY170117 A MY 170117A MY PI2014000238 A MYPI2014000238 A MY PI2014000238A MY PI2014000238 A MYPI2014000238 A MY PI2014000238A MY 170117 A MY170117 A MY 170117A
Authority
MY
Malaysia
Prior art keywords
methods
axis binding
treating cancer
mek inhibitors
binding antagonists
Prior art date
Application number
MYPI2014000238A
Inventor
Heather Maecker
Bryan Irving
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MY170117A publication Critical patent/MY170117A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
MYPI2014000238A 2011-08-01 2012-08-01 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors MY170117A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161574406P 2011-08-01 2011-08-01

Publications (1)

Publication Number Publication Date
MY170117A true MY170117A (en) 2019-07-05

Family

ID=46717934

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2014000238A MY170117A (en) 2011-08-01 2012-08-01 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
MYPI2017001198A MY193562A (en) 2011-08-01 2012-08-01 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2017001198A MY193562A (en) 2011-08-01 2012-08-01 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

Country Status (27)

Country Link
US (2) US9724413B2 (en)
EP (1) EP2739358B1 (en)
JP (3) JP6238459B2 (en)
KR (2) KR20190133790A (en)
CN (1) CN103842030B (en)
AR (2) AR087405A1 (en)
AU (4) AU2012290121B2 (en)
BR (2) BR112014002353B1 (en)
CA (1) CA2843595C (en)
CO (1) CO6900118A2 (en)
CR (1) CR20140034A (en)
EA (1) EA026924B1 (en)
EC (1) ECSP14013223A (en)
ES (1) ES2708669T3 (en)
IL (2) IL230647B (en)
MA (1) MA35366B1 (en)
MX (2) MX368257B (en)
MY (2) MY170117A (en)
PE (2) PE20190262A1 (en)
PH (2) PH12014500270A1 (en)
PL (1) PL2739358T3 (en)
SG (1) SG10201606284UA (en)
TR (1) TR201820873T4 (en)
TW (4) TWI654994B (en)
UA (1) UA117220C2 (en)
WO (1) WO2013019906A1 (en)
ZA (1) ZA201400612B (en)

Families Citing this family (417)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
ES2593027T3 (en) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Liposomal composition
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
DK3111938T3 (en) 2011-04-01 2019-07-01 Curis Inc PHOSPHOINOSIDID 3-KINASE BRAKE WITH A ZINC-BINDING GROUP
JP6038128B2 (en) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds
JP6238459B2 (en) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Method for treating cancer using PD-1 axis binding antagonist and MEK inhibitor
DK2806883T3 (en) 2012-01-25 2019-07-22 Dnatrix Inc BIOMARKERS AND COMBINATION THERAPIES WITH USING ONCOLYTIC VIRUS AND IMMUNOMODULATION
CN104411327A (en) 2012-03-12 2015-03-11 阿德瓦希斯公司 Suppressor cell function inhibition following listeria vaccine treatment
CN112587671A (en) 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted immunotherapy for cancer
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP2016515132A (en) * 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Combination and use of MEK inhibitor compounds with HER3 / EGFR inhibitor compounds
KR102389677B1 (en) * 2013-03-15 2022-04-21 제넨테크, 인크. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
EP2981281B1 (en) * 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JP6720075B2 (en) * 2013-05-31 2020-07-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Combination therapy for cancer
SG11201509742QA (en) * 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2014204856A1 (en) * 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Fatty acid anticancer derivatives and their uses
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
AR097279A1 (en) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd DERIVATIVES OF BENZIMIDAZOLIL-METIL UREA AS ALX RECEIVER AGONISTS
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
CA2920113A1 (en) * 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
AR097584A1 (en) 2013-09-12 2016-03-23 Hoffmann La Roche ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
EA034666B1 (en) * 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Anti-pd1 antibody and use thereof for treating cancer or viral infection, and antibody fragment
US10570204B2 (en) * 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
MX375378B (en) * 2013-09-27 2025-03-06 Genentech Inc ANTI-PDL1 ANTIBODY FORMULATIONS.
ES2714708T3 (en) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedures for the treatment of cancer in patients with elevated levels of Bim
EP3079772B1 (en) * 2013-12-10 2020-02-05 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
WO2015094992A1 (en) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
WO2015095404A2 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2014364606A1 (en) * 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
MX2016007885A (en) * 2013-12-17 2017-01-11 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody.
CN105899539B (en) 2014-01-10 2021-11-09 博笛生物科技有限公司 Compounds and compositions for immunotherapy
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
US20170037125A1 (en) 2014-02-04 2017-02-09 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
EA201691376A1 (en) 2014-02-04 2017-01-30 Пфайзер Инк. COMBINATION OF ANTAGONIST PD-1 AND VEGFR INHIBITOR FOR CANCER TREATMENT
US9676863B2 (en) 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US11230719B2 (en) 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
RU2016142476A (en) 2014-03-31 2018-05-07 Дженентек, Инк. COMBINED THERAPY, INCLUDING ANTI-ANGIOGENESIS AGENTS AND AGONISTS BINDING OX40
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
JP2017516779A (en) 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー Nucleoside derivatives for cancer treatment
PT3151921T (en) 2014-06-06 2019-11-21 Bristol Myers Squibb Co ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEIVER AND USES OF THE SAME
TWI726608B (en) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
ES2916923T3 (en) 2014-07-11 2022-07-06 Ventana Med Syst Inc Anti-PD-L1 antibodies and diagnostic uses thereof
SG11201700074YA (en) * 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
CA2955612C (en) 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
KR102524920B1 (en) 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 Anti-pd-1 antibodies
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
WO2016020856A2 (en) * 2014-08-05 2016-02-11 MabQuest SA Immunological reagents
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US10435470B2 (en) 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
US9546206B2 (en) 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
EP3180087B1 (en) 2014-08-12 2019-03-13 Alligator Bioscience AB Combination therapies with anti cd40 antibodies
EP3070102A1 (en) * 2015-03-18 2016-09-21 F. Hoffmann-La Roche AG Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
KR20170035945A (en) * 2014-08-14 2017-03-31 에프. 호프만-라 로슈 아게 Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
HRP20190881T1 (en) 2014-08-28 2019-07-12 Halozyme, Inc. COMBINATION THERAPY WITH HYALURONAN-DEGRADING ENZYME AND IMMUNOLOGICAL CONTROL POINT INHIBITOR
PT3524595T (en) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd HIGHLY PURE QUINOLINE DERIVATIVE AND METHOD FOR PRODUCTION THEREOF
CN112587672A (en) * 2014-09-01 2021-04-02 博笛生物科技有限公司 anti-PD-L1 conjugates for the treatment of tumors
US9535074B2 (en) 2014-09-08 2017-01-03 Merck Sharp & Dohme Corp. Immunoassay for soluble PD-L1
ES2771926T3 (en) 2014-09-13 2020-07-07 Novartis Ag Combination therapies
WO2016044189A1 (en) * 2014-09-15 2016-03-24 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
SMT202000562T1 (en) 2014-09-16 2020-11-10 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
JP6991857B2 (en) 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Treatment of cancer with TLR9 agonists with checkpoint inhibitors
IL250579B2 (en) 2014-10-10 2023-05-01 Innate Pharma Cd73 blockade
TWI716362B (en) 2014-10-14 2021-01-21 瑞士商諾華公司 Antibody molecules to pd-l1 and uses thereof
ES2753391T3 (en) 2014-10-14 2020-04-08 Halozyme Inc Adenosine deaminase 2 (ADA2) compositions, variants thereof and methods of use thereof
MX2017006320A (en) * 2014-11-17 2017-08-10 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
DK3221355T3 (en) * 2014-11-20 2020-12-07 Hoffmann La Roche Combination therapy with T cell activating bispecific antigen binding molecules CD3 and folate receptor 1 (FolR1) as well as PD-1 axis binding antagonists
CN105669862A (en) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 Anti-human PD-L1/KIR bispecific antibody, preparation method and application thereof
WO2016089873A1 (en) * 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
US10442819B2 (en) 2014-12-05 2019-10-15 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
US20160158360A1 (en) * 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
EP3226690B1 (en) 2014-12-05 2020-05-20 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
WO2016089830A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
EP3230498B1 (en) 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016106160A1 (en) * 2014-12-22 2016-06-30 Enumeral Biomedical Holdings, Inc. Methods for screening therapeutic compounds
JP2018503373A (en) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド Methods and compositions for cancer prognosis and treatment
JP2016155776A (en) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 Antitumor effect enhancer and antitumor agent
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
NZ733854A (en) 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
CA2978311A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating cancer
KR102662228B1 (en) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 Combination of PD-1 antagonists and VEGFR/FGFR/RET tyrosine kinase inhibitors to treat cancer
CN108112254B (en) 2015-03-13 2022-01-28 西托姆克斯治疗公司 anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016168133A1 (en) 2015-04-17 2016-10-20 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
US10702526B2 (en) * 2015-04-20 2020-07-07 Effector Therapeutics Inc. Inhibitors of immune checkpoint modulators and related methods
WO2016179576A1 (en) * 2015-05-07 2016-11-10 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
WO2016191397A1 (en) * 2015-05-22 2016-12-01 Td2 Inc. Benzamide and active compound compositions and methods of use
HK1252245A1 (en) 2015-05-27 2019-05-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
EP3763827A1 (en) * 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3302467A4 (en) * 2015-05-31 2019-01-02 Curegenix Corporation Combination compositions for immunotherapy
BR112017027227B1 (en) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd ANTI-CANCER AGENT
EP3310378B1 (en) * 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use
PH12017501857B1 (en) 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments
JP6896650B2 (en) 2015-06-17 2021-06-30 ジェネンテック， インコーポレイテッド Treatment of Locally Advanced or Metastatic Breast Cancer Using PD-1 Axle Antagonists and Taxanes
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
CN112710723B (en) 2015-07-13 2024-11-12 佰欧迪塞克斯公司 Predictive testing and classifier development approach for lung cancer patients who would benefit from PD-1 antibody drugs
CN114591433A (en) 2015-07-13 2022-06-07 西托姆克斯治疗公司 Anti-PD-1 antibody, activatable anti-PD-1 antibody and method of use
CN116059219A (en) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 Novel method for treating cancer using immunomodulation
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Preparations and methods for the treatment of cancer
DK3317301T3 (en) 2015-07-29 2021-06-28 Immutep Sas COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CR20180101A (en) 2015-08-13 2018-04-12 Merck Sharp & Dohme DI-NUCLEOTIC CYCLIC COMPOUNDS AS STING AGONISTS
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
JP6553726B2 (en) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 Tumor therapeutic agent
WO2017040990A1 (en) 2015-09-03 2017-03-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
PE20240096A1 (en) 2015-10-02 2024-01-18 Hoffmann La Roche BISPECIFIC ANTIBODIES SPECIFIC FOR A CO-STIMULATORY TNF RECEPTOR
CN108136010A (en) 2015-10-08 2018-06-08 宏观基因有限公司 For the conjoint therapy for the treatment of cancer
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
AU2016350701B2 (en) 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
TWI704154B (en) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 Novel compounds
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
US10538497B2 (en) 2015-12-15 2020-01-21 Merck Sharp & Dohme Corp. Compounds as indoleamine 2,3-dioxygenase inhibitors
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
GB201522311D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
JP7126941B2 (en) 2015-12-22 2022-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Combination of anti-PD-1 antibody and bispecific anti-CD20/anti-CD3 antibody for treating cancer
CN115252792A (en) 2016-01-07 2022-11-01 博笛生物科技有限公司 anti-EGFR combinations for the treatment of tumors
CN115350279A (en) 2016-01-07 2022-11-18 博笛生物科技有限公司 anti-HER 2 combinations for the treatment of tumors
CN106943596A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti-CD20 Combinations for Treating Tumors
JP6949030B2 (en) * 2016-01-08 2021-10-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Treatment of CEA-Positive Cancer Using PD-1 Axial Binding Antagonists and Anti-CEA / Anti-CD3 Bispecific Antibodies
CA3012055A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
WO2017125815A2 (en) 2016-01-22 2017-07-27 MabQuest SA Immunological reagents
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
WO2017136139A1 (en) 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
WO2017153433A1 (en) 2016-03-08 2017-09-14 Innate Pharma Siglec neutralizing antibodies
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
CN109310885B (en) 2016-03-15 2022-05-31 梅尔莎纳医疗公司 NaPi2b targeting antibody-drug conjugates and methods of use thereof
CN116196412A (en) * 2016-03-15 2023-06-02 中外制药株式会社 Methods of treating cancer using PD-1 axis binding antagonists and anti-GPC 3 antibodies
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
MA44483A (en) 2016-03-24 2019-01-30 Millennium Pharm Inc METHODS FOR TREATING GASTROINTESTINAL ADVERSE EVENTS OF IMMUNE ORIGIN IN ONCOLOGICAL IMMUNE TREATMENTS
WO2017167921A1 (en) 2016-03-30 2017-10-05 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
HRP20220936T1 (en) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
JP2019510802A (en) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Heterocyclic amides useful as protein modulators
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
WO2017189906A1 (en) * 2016-04-27 2017-11-02 Mira Dx, Inc. Immune-based treatment of kras-variant cancer patients
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
CA3023157A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
TWI755395B (en) 2016-05-13 2022-02-21 美商再生元醫藥公司 Combination of anti-pd-1 antibodies and radiation to treat cancer
MA45025A (en) * 2016-05-20 2019-03-27 Lilly Co Eli COMBINATION TREATMENT USING NOTCH AND PD-1 OR PD-L1 INHIBITORS
US20190298705A1 (en) 2016-06-08 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
KR20190015492A (en) 2016-06-08 2019-02-13 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Chemical compound
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP2019521166A (en) 2016-07-20 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Isoquinoline derivatives as PERK inhibitors
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
PT3500299T (en) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Use of a combination comprising a btk inhibitor for treating cancers
CN109790220A (en) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 Intermittent dosing of anti-CSF-1R antibodies in combination with macrophage activators
AU2017335839A1 (en) * 2016-09-29 2019-04-18 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane
US10414747B2 (en) 2016-10-04 2019-09-17 Merck Sharp & Dohme Corp. Benzo[b]thiophene compounds as sting agonists
KR20190062515A (en) 2016-10-06 2019-06-05 화이자 인코포레이티드 Usage of Abelipab for the Treatment of Cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
BR112019007145A2 (en) 2016-10-14 2019-07-02 Eisai R&D Man Co Ltd combination of a pd-1 antagonist and eribulin for the treatment of urothelial cancer
CA3041684C (en) * 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
CA3042249A1 (en) 2016-11-08 2018-05-17 Qilu Puget Sound Biotherapeutics Corporation Anti-pd1 and anti-ctla4 antibodies
EP3541825B1 (en) 2016-11-21 2026-04-01 Idenix Pharmaceuticals LLC Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN110662552A (en) 2016-11-30 2020-01-07 昂科梅德制药有限公司 Cancer Treatment Methods Containing TIGIT Binders
WO2018100535A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
JP2020500878A (en) 2016-12-01 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Combination therapy
AU2017375946A1 (en) * 2016-12-12 2019-06-20 Genentech, Inc. Methods of treating cancer using anti-PD-l1 antibodies and antiandrogens
CN110072553B (en) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 Combination of anti-CSF-1R antibody and anti-PD-L1 antibody for the treatment of tumors after failure of anti-PD-L1/PD1 therapy
CN108239149B (en) * 2016-12-25 2021-03-05 南京传奇生物科技有限公司 High-affinity, high-specificity and higher-functionality anti-human PD-L1 antibody with multiple antigen recognition epitopes
EP3566054A4 (en) 2017-01-05 2020-12-09 Biodesix, Inc. METHOD OF IDENTIFYING CANCER PATIENTS WITH CONTINUOUS BENEFITS OF IMMUNOTHERAPY IN SUBGROUPS WITH GENERALLY POOR PREDICTION
WO2018127570A1 (en) 2017-01-05 2018-07-12 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
PT3565844T (en) 2017-01-09 2023-05-02 Tesaro Inc Methods of treating cancer with anti-pd-1 antibodies
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
US11492367B2 (en) 2017-01-27 2022-11-08 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
US20200023071A1 (en) 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
JP6581320B2 (en) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pharmaceutical composition for tumor treatment
KR20240011262A (en) 2017-02-21 2024-01-25 리제너론 파아마슈티컬스, 인크. Anti-pd-1 antibodies for treatment of lung cancer
CN108503691B (en) * 2017-02-25 2021-07-23 复旦大学 A high-affinity peptide of human PD-L1 protein and its application
EP3585782A1 (en) 2017-02-27 2020-01-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
TW201834697A (en) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Combination therapies of her2-targeted antibody-drug conjugates
WO2018167778A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of diagnosing and prognosing cancer
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
CN110382544B (en) 2017-03-16 2023-12-22 先天制药公司 Compositions and methods for treating cancer
SG10202110707UA (en) 2017-03-30 2021-11-29 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN118515666A (en) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-Amino-quinoline derivatives
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN110869392A (en) 2017-05-16 2020-03-06 百时美施贵宝公司 Treatment of cancer with anti-GITR agonistic antibodies
JP2020522486A (en) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド Activatable anti-PDL1 antibody and method of using the same
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
KR20200015717A (en) 2017-06-09 2020-02-12 프로비던스 헬스 앤드 서비시즈 - 오레곤 Utilization of CD39 and CD103 for Identification of Human Tumor Reactive T Cells for Cancer Treatment
EP3634483A1 (en) 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Combination therapy
IL312120B2 (en) 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Medical preparation
TW202515616A (en) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 Use of anti-pd-1 antibody or antigen-binding fragment thereof in preparation of medicine for treatment of hepatocellular carcinoma (hcc)
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
BR112020000122A2 (en) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivatives of n- (3- (2- (4-chlorophenoxy) acetamido) bicyclo [1.1.1] pentan-1-yl) -2-cyclobutane-1-carboxamide and related compounds as inhibitors of atf4 for treatment against cancer and other diseases
AU2018298676A1 (en) 2017-07-10 2019-12-19 Innate Pharma Siglec-9-neutralizing antibodies
WO2019016174A1 (en) 2017-07-18 2019-01-24 Institut Gustave Roussy Method for assessing the response to pd-1/pdl-1 targeting drugs
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Indazole derivatives useful as perk inhibitors
US11312772B2 (en) 2017-08-04 2022-04-26 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
UY37866A (en) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd NEW SUBSTITUTED BENZOIMIDAZOL COMPOUNDS THAT REDUCE MYC PROTEIN (C-MYC) IN THE CELLS AND INHIBIT THE HISTONE ACETYLTRANSPHERASE OF P300 / CBP.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
WO2019068907A1 (en) 2017-10-06 2019-04-11 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
CN109663130B (en) * 2017-10-13 2021-06-29 江苏恒瑞医药股份有限公司 Use of a combination of a PD-1 antibody and a MEK inhibitor for the preparation of a medicament for the treatment of tumors
KR20200072507A (en) 2017-10-19 2020-06-22 데비오팜 인터네셔날 에스 에이 Combination products for cancer treatment
EP3703692B1 (en) 2017-11-01 2025-07-23 Merck Sharp & Dohme LLC Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
EP3709986B1 (en) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN111344287B (en) 2017-11-14 2023-12-19 默沙东有限责任公司 Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
TW201922291A (en) 2017-11-16 2019-06-16 瑞士商諾華公司 Combination therapies
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN111801334B (en) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 Treatment of Indolent or Aggressive B-Cell Lymphoma Using Combinations Containing BTK Inhibitors
CN108165536A (en) * 2017-12-11 2018-06-15 浙江大学 A kind of recombination oncolytic vaccinia virus and preparation method and application
WO2019118839A1 (en) 2017-12-15 2019-06-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
TW201930358A (en) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 Single-domain antibodies and variants thereof against TIGIT
EP3737373A4 (en) * 2018-01-10 2021-09-08 Array Biopharma, Inc. Methods and combination therapy to treat cancer
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP7383620B2 (en) 2018-01-31 2023-11-20 セルジーン コーポレイション Combination therapy using adoptive cell therapy and checkpoint inhibitors
EP3765006A4 (en) 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
AU2019233596A1 (en) 2018-03-14 2020-10-08 Merck Patent Gmbh Compounds and uses thereof to treat tumors in a subject
TWI841554B (en) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US12094587B2 (en) 2018-03-29 2024-09-17 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
EP3781687A4 (en) 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. NEW SUBSTITUTE RIG-I AGONISTS: COMPOSITIONS AND ASSOCIATED METHODS
AU2019264232A1 (en) 2018-05-04 2020-11-12 Tollys TLR3 ligands that activate both epithelial and myeloid cells
CN112512576A (en) 2018-05-04 2021-03-16 默克专利有限公司 Combined inhibition of PD-1/PD-L1, TGF beta and DNA-PK for the treatment of cancer
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2019217457A1 (en) * 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
SG11202011633SA (en) 2018-05-24 2020-12-30 Janssen Biotech Inc Psma binding agents and uses thereof
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
EP3810116B1 (en) 2018-05-31 2023-11-15 Merck Sharp & Dohme LLC Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
EP3802599B1 (en) 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
CN111867630B (en) 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 Antibodies, bispecific antibodies, ADCs and CARs targeting CLDN18.2 and their applications
MX2020012107A (en) 2018-06-18 2021-01-29 Innate Pharma Compositions and methods for treating cancer.
EP3810615B1 (en) 2018-06-20 2026-01-28 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
CN111902428B (en) 2018-07-03 2023-11-10 上海健信生物医药科技有限公司 A bispecific antibody and its use
WO2020007817A1 (en) * 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Novel bispecific agonistic 4-1bb antigen binding molecules
WO2020012339A1 (en) 2018-07-09 2020-01-16 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US20210301020A1 (en) 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
CN119955743A (en) * 2018-09-10 2025-05-09 上海锦斯生物技术有限公司 Modified oncolytic viruses, compositions and uses thereof
EP4410375A3 (en) * 2018-09-11 2024-11-06 iTeos Belgium SA Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AU2019337547A1 (en) 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
WO2020064971A1 (en) 2018-09-26 2020-04-02 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
US12152019B2 (en) 2018-10-17 2024-11-26 Merck Sharp & Dohme Llc Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
WO2020079692A1 (en) 2018-10-17 2020-04-23 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
JP2022513374A (en) 2018-10-22 2022-02-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド dosage
AU2019369340A1 (en) 2018-10-29 2021-05-20 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
TWI844571B (en) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092183A1 (en) 2018-11-01 2020-05-07 Merck Sharp & Dohme Corp. Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
EP3877366B1 (en) 2018-11-06 2026-01-28 Merck Sharp & Dohme LLC Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
BR112021007448A2 (en) * 2018-11-14 2021-10-26 Bayer Aktiengesellschaft PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER
EP3880202A2 (en) 2018-11-16 2021-09-22 ArQule, Inc. Pharmaceutical combination for treatment of cancer
KR20210093964A (en) 2018-11-20 2021-07-28 머크 샤프 앤드 돔 코포레이션 Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and uses thereof
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
CN113453678A (en) 2018-11-26 2021-09-28 德彪药业国际股份公司 Combination therapy for HIV infection
EP3886845B1 (en) 2018-11-28 2024-09-04 Merck Sharp & Dohme LLC Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
TW202039496A (en) 2018-11-30 2020-11-01 美商默沙東藥廠 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
AR117206A1 (en) 2018-11-30 2021-07-21 Glaxosmithkline Ip Dev Ltd OCTAHYDROPIRROLO [2,1-B] [1,3] THIAZEPIN-7-CARBOXAMIDE DERIVATIVES USEFUL IN HIV THERAPY AND FOR THE TREATMENT OF CANCER
SG11202104331YA (en) 2018-12-11 2021-05-28 Theravance Biopharma R&D Ip Llc Naphthyridine and quinoline derivatives useful as alk5 inhibitors
US12240867B2 (en) 2018-12-18 2025-03-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
KR20210106437A (en) 2018-12-20 2021-08-30 노파르티스 아게 Dosage regimens and pharmaceutical combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
CN113490528B (en) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
CN109879855B (en) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 Inhibitor targeting PD-L1 molecule on surface of tumor cell and application thereof
US12281109B2 (en) 2019-04-04 2025-04-22 Merck Sharp & Dohme Llc Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
BR112021020532A2 (en) 2019-04-19 2022-03-15 Janssen Biotech Inc Methods for treating prostate cancer with an anti-psma/cd3 antibody
SG11202111106WA (en) 2019-04-23 2021-11-29 Innate Pharma Cd73 blocking antibodies
AU2020276277B2 (en) 2019-05-15 2025-03-20 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
JP2022533194A (en) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド Benzo [B] [1,8] Diazanaphthalene Acetic Acid Derivatives and Usage
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
WO2020260547A1 (en) 2019-06-27 2020-12-30 Rigontec Gmbh Design method for optimized rig-i ligands
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021012092A1 (en) 2019-07-19 2021-01-28 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. A novel anti-pd-l1 antibody and use thereof
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CA3149482A1 (en) 2019-08-02 2021-02-11 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN114786776B (en) 2019-09-18 2026-03-24 拉姆卡普生物阿尔法股份公司 Bispecific antibodies against CEACAM5 and CD3
JP7732977B2 (en) 2019-09-20 2025-09-02 トランスジーン Combination of poxvirus encoding HPV polypeptides and IL-2 with anti-PD-L1 antibodies
JP7280387B2 (en) 2019-09-27 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド antigen binding protein
CN112724127B (en) 2019-10-28 2023-02-17 中国科学院上海药物研究所 Five-membered heteroepoxy carboxylic acid compound and its medical application
MX2022005056A (en) 2019-10-29 2022-05-18 Eisai R&D Man Co Ltd COMBINATION OF A PD-1 ANTAGONIST, A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR AND A CBP/BETA-CATENIN INHIBITOR FOR THE TREATMENT OF CANCER.
CN114728941A (en) 2019-11-22 2022-07-08 施万生物制药研发Ip有限责任公司 Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
WO2021113679A1 (en) 2019-12-06 2021-06-10 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
WO2021126725A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Novel substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
CN114981265B (en) 2019-12-18 2025-01-03 Ctxt私人有限公司 Compound
MX2022007759A (en) 2019-12-20 2022-07-19 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome.
EP4087583B1 (en) 2020-01-07 2026-04-22 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
TW202204339A (en) 2020-03-31 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 Substituted pyrimidines and methods of use
WO2021202984A1 (en) 2020-04-02 2021-10-07 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists
AU2021256925A1 (en) 2020-04-14 2022-11-03 Ares Trading S.A. Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
TW202206100A (en) 2020-04-27 2022-02-16 美商西健公司 Treatment for cancer
CN115836054B (en) 2020-05-06 2024-12-10 默沙东有限责任公司 IL4I1 inhibitors and methods of use
WO2021249969A1 (en) 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
CN116323607A (en) 2020-06-10 2023-06-23 施万生物制药研发Ip有限责任公司 Naphthyridine derivatives useful as ALK5 inhibitors
BR112022025856A2 (en) 2020-06-19 2023-01-10 Hoffmann La Roche ANTIBODY THAT BINDS CD3 AND CD19, POLYNUCLEOTIDE ISOLATED, HOST CELL, METHOD OF PRODUCING AN ANTIBODY THAT BINDS CD3 AND CD19, PHARMACEUTICAL COMPOSITION, USE OF THE ANTIBODY, METHOD FOR TREATING A DISEASE IN A SUBJECT AND INVENTION
CN115916199A (en) 2020-06-23 2023-04-04 诺华股份有限公司 Dosage regimens comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
US20230250173A1 (en) 2020-07-01 2023-08-10 Pfizer Inc. Biomarkers for pd-1 axis binding antagonist therapy
MX2023000197A (en) 2020-07-07 2023-02-22 BioNTech SE THERAPEUTIC RNA FOR HPV POSITIVE CANCER.
AU2021307410A1 (en) * 2020-07-13 2023-02-09 Verastem, Inc. Combination therapy for treating abnormal cell growth
KR20230050389A (en) * 2020-08-13 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 Methods for Redirecting IL-2 to Target Cells of Interest
KR20230087451A (en) 2020-09-02 2023-06-16 주식회사 파멥신 Combination therapy of a PD-1 antagonist and an antagonist to VEGFR-2 for treating cancer patients
ES2967381T3 (en) 2020-12-18 2024-04-30 Lamkap Bio Beta Ag Bispecific antibodies against CEACAM5 and CD47
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
US20240059789A1 (en) 2021-01-28 2024-02-22 Janssen Biotech, Inc. Psma binding proteins and uses thereof
CN117794929A (en) 2021-02-02 2024-03-29 法国施维雅药厂 Selective BCL-XL PROTAC Compounds and Methods of Use
CN116917273A (en) 2021-03-02 2023-10-20 葛兰素史克知识产权发展有限公司 Substituted pyridines as DNMT1 inhibitors
CN117321418A (en) 2021-03-18 2023-12-29 诺华股份有限公司 Cancer biomarkers and how to use them
TW202304506A (en) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2024511831A (en) 2021-03-31 2024-03-15 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Antigen binding proteins and combinations thereof
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
US12016860B2 (en) 2021-04-08 2024-06-25 Nurix Therapeutics, Inc. Combination therapies with Cbl-b inhibitor compounds
AU2022253351A1 (en) 2021-04-09 2023-10-12 Boehringer Ingelheim International Gmbh New scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2022227015A1 (en) 2021-04-30 2022-11-03 Merck Sharp & Dohme Corp. Il4i1 inhibitors and methods of use
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
JP2024525758A (en) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア Multispecific binding agents to CD40 and CD137 in combination therapy for cancer - Patents.com
CA3227386A1 (en) * 2021-07-28 2023-02-02 Jianing Huang Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
EP4377348A1 (en) 2021-07-30 2024-06-05 Seagen Inc. Treatment for cancer
WO2023039583A1 (en) * 2021-09-10 2023-03-16 Trustees Of Tufts College Anti-pd-1 immunoglobulin polypeptides and uses thereof
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
US20250228938A1 (en) * 2022-03-08 2025-07-17 Whitehead Institute For Biomedical Research The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
IL317102A (en) 2022-05-20 2025-01-01 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AR129423A1 (en) 2022-05-27 2024-08-21 Viiv Healthcare Co USEFUL COMPOUNDS IN HIV THERAPY
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
US20250230256A1 (en) 2022-06-16 2025-07-17 Lamkap Bio Beta Ltd Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
JP2025541738A (en) 2022-12-01 2025-12-23 ビオンテック・ソシエタス・エウロパエア Multispecific antibodies against CD40 and CD137 in combination with anti-PD1AB and chemotherapy
KR20250120305A (en) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Combination therapy involving a dual-specificity binding agent that binds to CLDN18.2 and CD3 and an immune checkpoint inhibitor
WO2024140919A1 (en) * 2022-12-29 2024-07-04 南京圣和药业股份有限公司 Anti-crtam/anti-pd-l1 antibody and use thereof
CN120957714A (en) 2023-03-07 2025-11-14 光治疗Asa公司 Bladder cancer treatment
AU2024234194A1 (en) 2023-03-10 2025-08-07 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
TW202502311A (en) 2023-03-29 2025-01-16 美商默沙東有限責任公司 Il4i1 inhibitors and methods of use
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025047983A1 (en) 2023-08-31 2025-03-06 国立大学法人 東京大学 Novel prodrug-type anticancer agent targeting cancer-specific enzyme activity
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025096843A1 (en) 2023-11-03 2025-05-08 Amgen Inc. Bispecific molecules
PY24103486A (en) 2023-11-22 2025-06-06 Servier Lab ANTI-CD74 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
AR134560A1 (en) 2023-12-08 2026-01-28 Astellas Pharma Inc COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS THAT BIND TO CLDN18.2 AND CD3 AND AGENTS THAT STABILIZE OR INCREASE CLDN18.2 EXPRESSION
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025213154A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025259515A2 (en) 2024-06-11 2025-12-18 Amgen Inc. Combination treatment
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
ATE300615T1 (en) 1990-08-29 2005-08-15 Genpharm Int TRANSGENIC MICE CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992009300A1 (en) 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DE69232137T2 (en) 1991-11-25 2002-05-29 Enzon Inc MULTIVALENT ANTI-BINDING PROTEINS
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ES2375931T3 (en) 1997-12-05 2012-03-07 The Scripps Research Institute HUMANIZATION OF ANTIBODY MURINO.
AU8856201A (en) * 2000-09-01 2002-03-13 Andel Inst Van Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
SG2013013339A (en) * 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
JP2006508974A (en) 2002-11-15 2006-03-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Combination chemotherapy comprising MEK inhibitor and capecitabine (CAPECITABINE) for treating cancer
AU2005252110B2 (en) 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
MX2007004781A (en) * 2004-10-20 2007-05-11 Applied Research Systems 3-arylamino pyridine derivatives.
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
RU2494107C2 (en) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Human monoclonal antibodies specific for programmed cell death 1 (pd1) protein and methods of treating cancer with using anti-pd1 antibodies either individually, or in combination with other immunotherapeutic agents
CN102206216B (en) 2005-06-22 2014-11-12 普莱希科公司 Pyrrolo[2,3-B] pyridine derivatives as protein kinase inhibitors
CN104356236B (en) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibody against programmed death ligand 1 (PD-L1)
HRP20110498T1 (en) 2005-10-07 2011-08-31 Exelixis AZETIDINS AS MAK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
ES2376771T3 (en) * 2006-08-21 2012-03-16 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008101840A1 (en) 2007-02-23 2008-08-28 F. Hoffmann-La Roche Ag Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells
US7919033B2 (en) * 2007-07-18 2011-04-05 Ngk Insulators, Ltd. Method of manufacturing honeycomb structure and manufacturing apparatus thereof
MX2010001581A (en) 2007-08-16 2010-03-15 Hoffmann La Roche Substituted hydantoins.
WO2009064675A1 (en) 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
EA201000910A1 (en) 2007-11-30 2011-04-29 Бристоль-Мейерз Сквибб Компани CONJUGAT "MONOCLONAL ANTIBODY AGAINST V7H4 / MEDICINE" AND METHODS OF ITS APPLICATION
AU2008343065B2 (en) 2007-12-19 2012-04-05 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
PT2242773T (en) 2008-02-11 2017-09-15 Cure Tech Ltd Monoclonal antibodies for tumor treatment
ES2392482T3 (en) 2008-02-29 2012-12-11 Array Biopharma, Inc. Imidazo [4,5-b] pyridine derivatives used as RAF inhibitors
JP2011513332A (en) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド N- (6-Aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as RAF inhibitors for the treatment of cancer
JP2011513331A (en) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド Pyrazole [3,4-b] pyridine RAF inhibitor
PE20091561A1 (en) 2008-02-29 2009-10-30 Array Biopharma Inc RAF INHIBITING COMPOUNDS AND METHODS FOR THEIR USE
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR20110028651A (en) 2008-07-11 2011-03-21 노파르티스 아게 Combination of (A) phosphoinositide 3-kinase inhibitors and (iii) modulators of the RAS / RAF / MBE pathway
CN102203132A (en) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Compositions and methods of use of PD-1 antagonists
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010056735A1 (en) * 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
KR101489045B1 (en) * 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Combinations of a pi3k inhibitor and a mek inhibitor
CA2779424A1 (en) 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
CA2779843A1 (en) 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
JP5998060B2 (en) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
WO2011156678A2 (en) 2010-06-11 2011-12-15 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Polyarylacetylenes containing siloxane, silane, and carborane moieties
JP6238459B2 (en) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Method for treating cancer using PD-1 axis binding antagonist and MEK inhibitor
PE20142312A1 (en) 2011-10-28 2015-01-25 Genentech Inc THERAPEUTIC COMBINATIONS AND METHODS TO TREAT MELANOMA
AU2014244424A1 (en) 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
SG11201509742QA (en) 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
SG11201700074YA (en) 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors

Also Published As

Publication number Publication date
AU2016201086A1 (en) 2016-03-10
ECSP14013223A (en) 2014-03-31
SG10201606284UA (en) 2016-09-29
JP6238459B2 (en) 2017-11-29
US9724413B2 (en) 2017-08-08
PH12018500365B1 (en) 2019-03-25
CA2843595A1 (en) 2013-02-07
BR122022000334B1 (en) 2023-03-21
WO2013019906A9 (en) 2014-03-20
MA35366B1 (en) 2014-08-01
CN103842030B (en) 2018-07-31
BR112014002353A2 (en) 2017-02-21
CO6900118A2 (en) 2014-03-20
ZA201400612B (en) 2016-06-29
CA2843595C (en) 2022-10-18
AU2016201086B2 (en) 2017-11-02
MY193562A (en) 2022-10-19
AU2012290121B2 (en) 2015-11-26
IL230647B (en) 2020-05-31
EA026924B1 (en) 2017-05-31
JP2018008963A (en) 2018-01-18
TW201318638A (en) 2013-05-16
AR087405A1 (en) 2014-03-19
WO2013019906A1 (en) 2013-02-07
BR112014002353B1 (en) 2022-09-27
MX368257B (en) 2019-09-26
EP2739358B1 (en) 2018-11-28
EP2739358A1 (en) 2014-06-11
PH12018500365A1 (en) 2019-03-25
MX2019011424A (en) 2019-11-01
CR20140034A (en) 2014-07-23
TWI835048B (en) 2024-03-11
PE20190262A1 (en) 2019-02-25
AR122743A2 (en) 2022-10-05
IL230647A0 (en) 2014-03-31
MX2014001319A (en) 2014-02-27
KR102049817B1 (en) 2019-12-02
AU2012290121A1 (en) 2013-05-09
AU2018200559A1 (en) 2018-02-15
PL2739358T3 (en) 2019-04-30
ES2708669T3 (en) 2019-04-10
TW201840336A (en) 2018-11-16
PE20141693A1 (en) 2014-11-24
AU2019206076A1 (en) 2019-08-08
KR20190133790A (en) 2019-12-03
JP2014525918A (en) 2014-10-02
KR20140063643A (en) 2014-05-27
JP6762274B2 (en) 2020-09-30
TWI654994B (en) 2019-04-01
US10646567B2 (en) 2020-05-12
TW202216199A (en) 2022-05-01
CN103842030A (en) 2014-06-04
IL274059B (en) 2021-10-31
BR112014002353A8 (en) 2021-09-28
US20140341902A1 (en) 2014-11-20
JP2019196357A (en) 2019-11-14
AU2018200559B2 (en) 2019-05-09
US20180021431A1 (en) 2018-01-25
PH12014500270A1 (en) 2014-03-31
UA117220C2 (en) 2018-07-10
TR201820873T4 (en) 2019-01-21
TW202114735A (en) 2021-04-16
NZ620411A (en) 2016-07-29
EA201490369A1 (en) 2014-08-29
IL274059A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
PH12018500365B1 (en) Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
ZA202110554B (en) Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
MX2019003942A (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists.
MX2016007885A (en) Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody.
NZ706836A (en) Methods of treating cancer
MX2013011329A (en) Combinations of akt inhibitor compounds and erlotinib, and methods of use.
MX369691B (en) Glutamase inhibitors and method of use.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
WO2011146568A8 (en) Predicting response to a her inhibitor
MX2014013752A (en) Nampt inhibitors.
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502513A1 (en) Nampt inhibitors
MX348040B (en) Hedgehog antagonists having zinc binding moieties.
MX348311B (en) Nampt inhibitors.
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
WO2013013238A3 (en) Compounds and related compositions and methods of use
NZ721522A (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists